IN THE NEWS

« Previous Release | Next Release »

BOTHELL, Wash., -- Cardiac Science, a global leader in advanced cardiac diagnosis, resuscitation, rehabilitation, and informatics products, today added DICOM connectivity to its Quinton Q-Stress cardiac stress testing system and Quinton Q-Tel cardiac rehabilitation system.

"With DICOM and HL7 technologies, Cardiac Science is prepared to serve the hospitals and physicians ready to take advantage of the Economic Stimulus Bill," Director of Diagnostic Marketing for Cardiac Science Rene Mitchell said. "This is another critical step in our path to be the diagnostic connectivity leaders."

The Quinton Q-Stress can now connect to hospital information systems (HIS) and electronic medical records (EMR) in the way that works best for each practice or hospital. Among its benefits,

    --  Less administration: Demographics, billing, and procedure codes can be
        imported via bi-directional communication using DICOM or HL7.
    --  Fewer errors and lost billing: Comprehensive tests can be exported to
        minimize documentation errors.
    --  Interoperability: Q-Stress can connect to virtually any EMR, HIS, PACS,
        and other healthcare systems including GE Muse.
    --  Easy implementation: Little to no HIS customization is required.

    --  Easy maintenance: There is little to no difficulty updating links as an
        HIS evolves.

First to offer DICOM connectivity to cardiac rehab segment

Cardiac Science is the first to offer DICOM connectivity to the cardiac rehabilitation segment. With the addition of DICOM and HL7 technology, Q-Tel now supports all the latest industry standards for connectivity.

"More cardiac rehab centers will connect their patient records to HIS systems. Our DICOM and HL7 connectivity options will make the move much easier," Mitchell added.

About Cardiac Science

Cardiac Science, a wholly owned subsidiary of Opto Circuits (India) Ltd., develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, PC-based diagnostic workstations, Holter monitoring systems, hospital defibrillators, vital signs monitors, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick^®, HeartCentrix^®, Powerheart^®, and Quinton^® brands, is headquartered in Bothell, Washington. With customers in almost 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

Forward-Looking Statements

This press release contains forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward-looking statements in this press release include, but are not limited to, those relating to Cardiac Science Corporation's future AED sales in Japan, expected shipments of backordered products in the fourth quarter of 2010, and expectations regarding the closing of the transaction with Opto Circuits. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results and performance may vary significantly from those expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks include those more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2009, as updated by subsequent quarterly reports on Form 10-Q. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

For updates and information on worldwide defibrillation and cardiac monitoring, find us on Facebook at http://facebook.com/cardiacscience, the Cardiac Science blog at http://www.cardiacscience.com/blog, Twitter at http://twitter.com/cardiacscience, and YouTube at http://budurl.com/CSonYT

For more information, contact (media) info@cardiacscience.com | (investors) ir@optoindia.com | +91.80.2852.8088